Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.
Alcohol Clin Exp Res. 2010 Feb;34 Suppl 1:S25-33. doi: 10.1111/j.1530-0277.2008.00850.x. Epub 2009 Dec 16.
Deficiency of ADAMTS13 (adisintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13) results in an increase in unusually large von Willebrand factor multimer (UL-VWFM) of the plasma and finally causes microcirculatory disturbance. Our previous study demonstrated that the imbalance of increased UL-VWFM over decreased ADAMTS13 activity may contribute to the development of multiorgan failure in patients with alcoholic hepatitis (AH). The aim of this study was to explore the potential mechanism to reduce the activity of plasma ADAMTS13.
Plasma cytokine levels including interleukin (IL)-6, IL-8, and tumor necrosis factor-alpha (TNF-alpha), plasma endotoxin concentration, and the plasma inhibitor against ADAMTS13 were determined together with ADAMTS13 activity, VWF antigen (VWF:Ag), and UL-VWFM in 24 patients with AH and 5 patients with severe alcoholic hepatitis (SAH).
The concentrations of IL-6, IL-8, and TNF-alpha on admission were significantly higher in patients with SAH than in those with AH and controls. The ADAMTS13 activity concomitantly decreased, and the VWF:Ag progressively elevated with increasing concentrations of these cytokines from normal range to over 100 pg/ml. Plasma endotoxin concentration was markedly higher in patients with SAH (mean 52.3 pg/ml) and AH (21.7 pg/ml) than in controls (7.9 pg/ml). The endotoxin concentration inversely correlated with ADAMTS13 activity and was higher in patients with UL-VWFM than those without. The inhibitor was detected in 4 patients with SAH (0.9 to 2.1 BU/ml) and 6 patients with AH (0.5 to 1.6 BU/ml). Patients with the inhibitor showed lower functional liver capacity, higher endotoxin concentration, and marked inflammatory signs than those without. At the recovery stage, the ADAMTS13 activity increased to normal range, the VWF:Ag decreased, and the UL-VWFM disappeared with the decrease in the concentrations of cytokines and endotoxin, and the disappearance of the inhibitor.
Decreased ADAMTS13 activity and increased VWF:Ag could be induced not only by pro-inflammatory cytokinemia, but also by its inhibitor, both of which may be closely related to enhanced endotoxemia in patients with AH and SAH.
ADAMTS13(解整合素样金属蛋白酶与血小板反应蛋白 1 型基质金属蛋白酶 13)的缺乏会导致血浆中异常大的 von Willebrand 因子多聚体(UL-VWFM)增加,最终导致微循环障碍。我们之前的研究表明,增加的 UL-VWFM 与降低的 ADAMTS13 活性之间的失衡可能导致酒精性肝炎(AH)患者多器官衰竭的发展。本研究旨在探讨降低血浆 ADAMTS13 活性的潜在机制。
共检测了 24 例酒精性肝炎(AH)患者和 5 例严重酒精性肝炎(SAH)患者的血浆细胞因子水平(白细胞介素(IL)-6、IL-8 和肿瘤坏死因子-α(TNF-α))、血浆内毒素浓度、ADAMTS13 抑制剂以及 ADAMTS13 活性、血管性血友病因子抗原(VWF:Ag)和 UL-VWFM。
SAH 患者入院时的 IL-6、IL-8 和 TNF-α 浓度明显高于 AH 患者和对照组。ADAMTS13 活性同时降低,VWF:Ag 逐渐升高,这些细胞因子的浓度从正常范围升高至超过 100pg/ml。SAH(平均 52.3pg/ml)和 AH(21.7pg/ml)患者的血浆内毒素浓度明显高于对照组(7.9pg/ml)。内毒素浓度与 ADAMTS13 活性呈负相关,且 UL-VWFM 患者的内毒素浓度高于无 UL-VWFM 患者。在 4 例 SAH(0.9 至 2.1 BU/ml)和 6 例 AH(0.5 至 1.6 BU/ml)患者中检测到抑制剂。与无抑制剂患者相比,有抑制剂的患者肝功能更差,内毒素浓度更高,炎症迹象更明显。在恢复期,ADAMTS13 活性恢复正常,VWF:Ag 降低,UL-VWFM 消失,同时细胞因子和内毒素浓度降低,抑制剂消失。
ADAMTS13 活性降低和 VWF:Ag 增加不仅可由促炎细胞因子诱导,还可由其抑制剂诱导,两者可能与 AH 和 SAH 患者增强的内毒素血症密切相关。